RevoluGROUP Canada Inc. Announces CEO’s Resignation Due to Health Reasons
The Board has reviewed comprehensive medical history dating back to November 2022, demonstrating continuous inquiries into a pulmonary pathology associated with suspected chronic obstructive pulmonary disease alleviated by doctor-prescribed Symbicort. Despite mandated vaccinations and correctly administered boosters, Mr. Marshall suffered three particularly aggressive bouts of...
Stay connected